Loading people...
Greg Parekh is a Managing Partner at New Rhein Healthcare Investors, a firm specializing in strategic investments within the healthcare sector. He is responsible for leading investment strategies and overseeing portfolio companies.
Greg Parekh primarily invests in companies across the healthcare industry through New Rhein Healthcare Investors. His focus areas include pharmaceuticals, biotechnology, medical devices, diagnostics, and digital health solutions, targeting innovative companies with strong growth potential.
Greg Parekh works as a Managing Partner at New Rhein Healthcare Investors.
Greg Parekh stands as a pivotal figure in healthcare private equity, serving as a Managing Partner at New Rhein Healthcare Investors. In this capacity, he plays a critical role in shaping the firm's investment strategy and overseeing its portfolio of innovative healthcare companies. His leadership is instrumental in identifying and executing investments that promise significant advancements within the global healthcare landscape.
New Rhein Healthcare Investors, under Greg Parekh's guidance, is dedicated to strategic investments across a broad spectrum of the healthcare industry. The firm's focus areas typically encompass pharmaceuticals, biotechnology, medical devices, diagnostics, and emerging digital health solutions. Greg Parekh's expertise allows him to pinpoint companies with strong growth potential, disruptive technologies, and robust market positions. He is particularly interested in opportunities that can address unmet medical needs, improve patient outcomes, and enhance the efficiency of healthcare delivery systems. His approach involves a deep dive into market trends, regulatory environments, and technological innovations to ensure that investments are well-positioned for long-term success.
While specific details of Greg Parekh's early career are not publicly detailed, his extensive experience in finance and the healthcare sector is evident through his leadership role at New Rhein Healthcare Investors. Professionals in his position typically bring a rich background from investment banking, private equity, venture capital, or senior operational roles within healthcare companies. This diverse experience equips him with a comprehensive understanding of both the financial intricacies and the operational challenges inherent in the healthcare industry. His career trajectory likely reflects a consistent commitment to identifying value, fostering growth, and navigating complex market dynamics. This foundation enables him to provide strategic guidance to portfolio companies, helping them scale, innovate, and achieve their full potential.
At New Rhein Healthcare Investors, Greg Parekh is not merely an investor but a strategic partner to the companies he supports. He works closely with management teams to implement growth strategies, optimize operations, and explore new market opportunities. His involvement extends beyond capital injection, encompassing strategic planning, operational improvements, and M&A advisory. Through this hands-on approach, he aims to create sustainable value for both investors and the healthcare ecosystem. His vision is to back companies that are not only financially sound but also contribute meaningfully to the advancement of global health, ultimately leading to better patient care and more efficient healthcare systems worldwide. His leadership reinforces New Rhein Healthcare Investors' reputation as a discerning and impactful player in the healthcare investment arena.
Greg Parekh is the Founder and Managing Partner of New Rhein Healthcare Investors, as well as the CEO of Alveus Therapeutics, based in Philadelphia, Pennsylvania. Previously, he served as Head of Mergers and Acquisitions at Novartis, executing over 20 transactions valued at more than $70 billion and managing the Alcon integration. He also operated as CEO of BioClinica, leading the clinical trial services firm through a $123 million take-private sale in 2013. Earlier in his career, Parekh headed the European Healthcare Group at Deutsche Bank and worked at Bear Stearns, having earned a PhD in Economics from Northwestern University. Through New Rhein, his current focus centers on middle-market private equity investments in healthcare therapeutics and medical devices. He typically deploys $20 million to $40 million per portfolio company to commercialize proven products with new clinical applications.
